Mubadala Investment Company related stories
All articles and analysis
Women of Influence 2026: L-PWe put a spotlight on the women shaping the private markets landscape.
Women of Influence 2026: A-FThe women making an impact across infrastructure, private debt, real estate, private equity and venture capital.
Mubadala: Healthcare PE's real test is patients, not just returnsThe sovereign fund can write tickets up to $2bn per transaction, Josh Zhou, head of healthcare private equity for North America, tells PEI.
Global Investor 150: The 2026 top 10Between them, the 10 largest investors on this year’s Global Investor 150 ranking have $1.1trn allocated to private equity, with an average allocation of 21%.
LPs go direct for GP stakesInstitutional investors are voicing an interest in stepping outside the familiar fund structure to invest directly in GPs. The move could change the GP stakes market and create a new class of shareholders.
Iran conflict could accelerate 'rebalancing' among Gulf LPsThe region's $5.4trn of sovereign wealth fund capital has been turning inwards in recent years.
Side Letter: M&G's liquidity playIn today's edition, A UK asset management giant taps the secondaries market in a novel way; Q4 exit volume disappoints; APAC's second-largest PE market sees another large fund close.
Spotlight on LPACs in high-profile continuation vehicle spatDo limited partner advisory committees have any relevance in a world where a sole LP wants to have its day in court?
Number Crunch: MENA is an oasis in a fundraising desertThe Middle East and North Africa region has become increasingly attractive to managers as they attempt to tap its massive stock of sovereign wealth fund capital.
Side Letter: LP insight updateLPs share their investment priorities for a changing world. Plus: how institutional heavyweights are approaching impact in 2025; and New Jersey Division of Investment mulls a secondaries sale. Here's today's brief, for our valued subscribers only.